<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192634</url>
  </required_header>
  <id_info>
    <org_study_id>STEAL</org_study_id>
    <secondary_id>ACTRN012605000505606</secondary_id>
    <nct_id>NCT00192634</nct_id>
  </id_info>
  <brief_title>A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study</brief_title>
  <official_title>A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination antiretroviral therapy for the treatment of HIV has a high pill burden. Two
      dual-tablets, abacavir-lamivudine and tenofovir-emtricitabine, are now licensed in the United
      States and will be available in Australia in December 2005. Data available suggest that the
      potency of these tablets are similar in controlling replication of the HIV virus, but not
      have not been directly compared in regard to clinically significant toxicities. We therefore
      aim to compare the overall safety and efficacy of the two dual-tablets over a 2 year period
      in HIV infected adults. We hypothesise that the two dual-NRTI treatments will be similar in
      efficacy and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare the overall safety and efficacy of two dual-NRTI, once
      daily, tablets over a 2 year period in HIV infected adults.

      The study is a randomised, multi-centre, 2 year study of two dual NRTI, once daily tablets in
      subjects with HIV, currently taking two individual NRTIs as part of their therapy. 350
      subjects will be randomised in a 1:1 ratio to either:

        1. tenofovir (TDF) 300mg + emtricitabine (FTC) 200mg OR

        2. abacavir (ABC) 600mg + lamivudine (3TC) 300mg. Subjects will cease their current
           individual NRTI treatment, commence their randomised dual NRTI tablet, and continue on
           their current NNRTI or PI therapy.

      Subjects will be stratified by the type of NRTI they are currently taking (ABC, TDF or
      other); whether they are currently taking a protease inhibitor (yes or no); and by the site
      where they are randomised. A study plan is enclosed

      Subjects will be closely monitored (at 1 month and then every 3 months until week 96) for
      safety by evaluating the incidence and severity of adverse effects/abnormal laboratory
      parameters. Study investigations enclosed. It is optional whether subjects also provide
      plasma, serum and cells (PBMCs) for storage. These samples will be available for analysis for
      sub-studies agreed to through the IVRN expression of interest network.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>virological failure defined by HIV RNA&gt;400copies/mL plasma on 2 consecutive occasions ³4 wks apart(Roche Amplicor v1.5, LLD 50 copies/mL)</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma HIV RNA&lt;50copies/mL; time to virological failure (VF); virological resistance in those with VF; all SAEs; use of concomitant meds for toxicity; adherence; QoL; CD4+lymphocyte count; full blood count; biochemistry; lipid parameters</measure>
    <time_frame>Week 48 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycaemic parameters; DEXA parameters; resolution of AEs; progression to AIDS; death; discontinuation of ART.</measure>
    <time_frame>Week 48 and 96</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abacavir 600mg/Lamivudine 300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300mg/emtricitabine 200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine 200mg - Tenofovir 300mg</intervention_name>
    <description>1 tablet once daily for 96 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir 600mg - Lamivudine 300mg</intervention_name>
    <description>1 tablet once daily for 96 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Kivexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented HIV infection

          -  age at least 18 years

          -  stable (≥ to 12 weeks) ART including at least two NRTIs, currently well tolerated,
             with no plan to change any other component of the ART regimen at or after baseline

          -  HIV RNA &lt; 50 copies/mL plasma for the preceding 12 weeks

          -  GFR ≥ 70 mL/min/1.73m2 (estimated by the abbreviated MDRD equation23 estimated GFR =
             186 x ([SCR/88.4]-1.154) x age-0.203 x (0.742 if female) x (1.210 if African-American)

          -  provision of written, informed consent

        Exclusion Criteria:

          -  HLA-B*5701 positive at screening OR evidence of previous ABC hypersensitivity OR
             clinical failure in participants taking abacavir for at least 30 days

          -  current therapy comprising triple NRTI therapy alone

          -  current use of ABC/3TC FDC (Kivexa) or TDF/FTC FDC (Truvada)

          -  history of non-traumatic osteoporotic fracture

          -  prior hypersensitivity or intolerance to ABC, 3TC, TDF or FTC

          -  prior clinical failure to a regimen containing ABC or TDF

          -  prior use of TDF for control of previously active hepatitis B (HBsAg+ or HBV DNA+) in
             patients likely to be resistant to 3TC/FTC

          -  current therapy including unboosted atazanavir

          -  concurrent use of aminoglycosides, IV amphotericin B, cidofovir, cisplatin, foscarnet,
             IV pentamidine, probenecid, adefovir or immunomodulatory agents

          -  clinical evidence of cirrhosis (e.g. smooth liver, no features of portal hypertension)

          -  creatinine clearance &lt; 50 mL/min (estimated by the Cockcroft-Gault equation)18,19

               -  Male: (140 - age in years) x (wt in kg) = CLCr (mL/min) 0.814 x (serum creatinine
                  in µmol/L)

               -  Female:(140 - age in years) x (wt in kg) x 0.85 = CLCr (mL/min) 0.814 x (serum
                  creatinine in µmol/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Carr, MD FRACP FRCPA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holdsworth House General Practice - Byron Bay</name>
      <address>
        <city>Byron Bay</city>
        <state>New South Wales</state>
        <zip>2481</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lismore Sexual Health Clinic - Northen Rivers Area Health Service</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2304</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>407 Doctors</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albion Street Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House General Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taylor Square Private Clinic</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic 16, Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burwood Road Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2134</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Health Service</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QLD Health - AIDS Medical Unit</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gladstone Road Medical Centre</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doll's House Clinic - Cairns Base Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Sexual Health Clinic</name>
      <address>
        <city>Miami</city>
        <state>Queensland</state>
        <zip>4220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic 87, Nambour Hospital</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Care and Prevention Programme - Adelaide University</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlton Clinic</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Sexual Health Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prahran Market Clinic</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3141</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre Clinic</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3182</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3403</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Hospital</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <results_reference>
    <citation>http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=18</citation>
  </results_reference>
  <results_reference>
    <citation>Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009 Nov 15;49(10):1591-601. doi: 10.1086/644769.</citation>
    <PMID>19842973</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>May 24, 2011</last_update_submitted>
  <last_update_submitted_qc>May 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof Sean Emery</name_title>
    <organization>The National Centre in HIV Epidemiology and Clinical Research</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>nucleoside analogue reverse transcriptase</keyword>
  <keyword>fixed dose combination</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

